Boxer Capital Management
Latest statistics and disclosures from Boxer Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are TNGX, RVMD, ABVX, QURE, KOD, and represent 48.28% of Boxer Capital Management's stock portfolio.
- Added to shares of these 10 stocks: ABVX (+$54M), QTTB (+$40M), QURE (+$39M), REPL (+$31M), CELC (+$20M), CAPR (+$19M), DFTX (+$19M), KYMR (+$12M), PGEN (+$9.4M), OCUL (+$9.3M).
- Started 12 new stock positions in EDSA, SYRE, NMRA, QTTB, STTK, FTH, IMTX, FBRX, RLAY, Odyssey Therapeutics. MPLT, KZIA.
- Reduced shares in these 4 stocks: TERN (-$20M), Soleno Therapeutics (-$6.7M), ALLO, Kalvista Pharmaceuticals.
- Sold out of its positions in Kalvista Pharmaceuticals, Soleno Therapeutics, TERN.
- Boxer Capital Management was a net buyer of stock by $311M.
- Boxer Capital Management has $1.3B in assets under management (AUM), dropping by 74.33%.
- Central Index Key (CIK): 0002018299
Tip: Access up to 7 years of quarterly data
Positions held by Boxer Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Boxer Capital Management
Boxer Capital Management holds 63 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Tango Therapeutics (TNGX) | 25.6 | $340M | 11M | 31.26 |
|
|
| Revolution Medicines (RVMD) | 7.1 | $94M | 500k | 187.28 |
|
|
| Abivax Sa Sponsored Ads (ABVX) | 6.1 | $81M | +202% | 605k | 133.26 |
|
| Uniqure Nv SHS (QURE) | 5.2 | $69M | +127% | 1.5M | 46.06 |
|
| Kodiak Sciences (KOD) | 4.3 | $58M | +8% | 1.5M | 38.96 |
|
| Kymera Therapeutics (KYMR) | 3.7 | $49M | +30% | 429k | 114.67 |
|
| Definium Therapeutics Com Shs (DFTX) | 3.5 | $47M | +66% | 999k | 47.04 |
|
| Replimune Group (REPL) | 3.3 | $44M | +238% | 4.0M | 11.07 |
|
| Celcuity (CELC) | 3.3 | $44M | +85% | 417k | 104.62 |
|
| Q32 Bio (QTTB) | 3.0 | $40M | NEW | 3.1M | 12.74 |
|
| Capricor Therapeutics Com New (CAPR) | 2.5 | $34M | +136% | 1.4M | 24.08 |
|
| Precigen (PGEN) | 2.2 | $29M | +47% | 5.2M | 5.70 |
|
| Corcept Therapeutics Incorporated (CORT) | 2.2 | $29M | +34% | 336k | 86.95 |
|
| Surrozen Com New (SRZN) | 2.0 | $27M | +44% | 1.1M | 24.39 |
|
| Protagonist Therapeutics (PTGX) | 1.6 | $21M | 170k | 122.58 |
|
|
| Vir Biotechnology (VIR) | 1.4 | $19M | 1.9M | 10.19 |
|
|
| Vaxcyte (PCVX) | 1.4 | $19M | 325k | 58.13 |
|
|
| Urogen Pharma (URGN) | 1.4 | $18M | 500k | 36.80 |
|
|
| Corvus Pharmaceuticals (CRVS) | 1.2 | $16M | 1.1M | 14.94 |
|
|
| Ptc Therapeutics I (PTCT) | 1.2 | $16M | 200k | 81.57 |
|
|
| Praxis Precision Medicines I Com New (PRAX) | 1.2 | $16M | 47k | 334.79 |
|
|
| Amylyx Pharmaceuticals (AMLX) | 1.1 | $14M | 800k | 17.96 |
|
|
| Ocular Therapeutix (OCUL) | 1.0 | $13M | +271% | 1.3M | 9.82 |
|
| Ocuphire Pharma (IRD) | 0.9 | $12M | +25% | 2.8M | 4.11 |
|
| Palisade Bio (PALI) | 0.8 | $10M | 4.8M | 2.09 |
|
|
| Apogee Therapeutics (APGE) | 0.7 | $9.3M | 70k | 132.73 |
|
|
| Spyre Therapeutics Com New (SYRE) | 0.7 | $8.9M | NEW | 100k | 88.78 |
|
| Cogent Biosciences (COGT) | 0.7 | $8.7M | 225k | 38.70 |
|
|
| Cytokinetics Com New (CYTK) | 0.6 | $8.5M | 100k | 85.19 |
|
|
| Relay Therapeutics (RLAY) | 0.6 | $8.4M | NEW | 450k | 18.71 |
|
| Crescent Biopharma | 0.6 | $8.2M | 454k | 18.00 |
|
|
| Contineum Therapeutics Cl A (CTNM) | 0.6 | $8.1M | 494k | 16.39 |
|
|
| Kazia Therapeutics Sponsored Ads (KZIA) | 0.6 | $7.9M | NEW | 560k | 14.08 |
|
| Shattuck Labs (STTK) | 0.5 | $6.9M | NEW | 1.0M | 6.94 |
|
| Avalo Therapeutics Com New (AVTX) | 0.5 | $6.9M | +25% | 375k | 18.48 |
|
| Forte Biosciences Com New (FBRX) | 0.4 | $5.8M | NEW | 275k | 21.25 |
|
| Relmada Therapeutics (RLMD) | 0.4 | $5.8M | 842k | 6.92 |
|
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 0.4 | $5.4M | 275k | 19.47 |
|
|
| Zura Bio Class A Ord Shs (ZURA) | 0.4 | $5.3M | 900k | 5.90 |
|
|
| Cybin Com New (HELP) | 0.4 | $5.2M | +23% | 790k | 6.61 |
|
| Odyssey Therapeutics Common Stock | 0.4 | $5.1M | NEW | 275k | 18.71 |
|
| Immatics SHS (IMTX) | 0.4 | $4.8M | NEW | 475k | 10.13 |
|
| Faeth Therapeutics Com New (FTH) | 0.3 | $4.5M | NEW | 181k | 25.00 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 0.3 | $4.0M | 75k | 53.67 |
|
|
| Oric Pharmaceuticals (ORIC) | 0.3 | $3.8M | +98% | 350k | 10.83 |
|
| An2 Therapeutics (ANTX) | 0.3 | $3.6M | 749k | 4.84 |
|
|
| Neumora Therapeutics (NMRA) | 0.3 | $3.4M | NEW | 2.0M | 1.70 |
|
| Inovio Pharmaceuticals Com Shs (INO) | 0.2 | $3.1M | +20% | 2.8M | 1.10 |
|
| Allogene Therapeutics (ALLO) | 0.2 | $3.1M | -44% | 1.5M | 2.08 |
|
| Solid Biosciences Com New (SLDB) | 0.2 | $3.0M | 300k | 9.99 |
|
|
| Karyopharm Therapeutics Com New (KPTI) | 0.2 | $3.0M | 303k | 9.77 |
|
|
| Clene Com New (CLNN) | 0.2 | $2.9M | 478k | 6.16 |
|
|
| Sarepta Therapeutics (SRPT) | 0.2 | $2.7M | 150k | 17.97 |
|
|
| Maplight Therapeutics (MPLT) | 0.2 | $2.7M | NEW | 75k | 35.84 |
|
| Nurix Therapeutics (NRIX) | 0.2 | $2.4M | 100k | 24.26 |
|
|
| Lb Pharmaceuticals Com Shs (LBRX) | 0.2 | $2.3M | 70k | 32.45 |
|
|
| Edesa Biotech Com New (EDSA) | 0.1 | $1.7M | NEW | 205k | 8.13 |
|
| Adagio Therapeutics (IVVD) | 0.1 | $1.3M | 1.5M | 0.87 |
|
|
| Upstream Bio (UPB) | 0.1 | $1.0M | 150k | 6.92 |
|
|
| Milestone Pharmaceuticals (MIST) | 0.1 | $893k | 667k | 1.34 |
|
|
| Pepgen (PEPG) | 0.0 | $491k | 273k | 1.80 |
|
|
| Regenxbio Inc equity us cm (RGNX) | 0.0 | $180k | 15k | 11.98 |
|
|
| Surrozen *w Exp 08/01/203 (SRZNW) | 0.0 | $1.1k | 67k | 0.02 |
|
Past Filings by Boxer Capital Management
SEC 13F filings are viewable for Boxer Capital Management going back to 2024
- Boxer Capital Management 2026 Q2 filed Aug. 14, 2026
- Boxer Capital Management 2026 Q1 filed May 15, 2026
- Boxer Capital Management 2025 Q1 restated filed Feb. 17, 2026
- Boxer Capital Management 2025 Q2 restated filed Feb. 17, 2026
- Boxer Capital Management 2025 Q3 restated filed Feb. 17, 2026
- Boxer Capital Management 2025 Q4 filed Feb. 17, 2026
- Boxer Capital Management 2025 Q3 filed Nov. 14, 2025
- Boxer Capital Management 2025 Q2 filed Aug. 14, 2025
- Boxer Capital Management 2025 Q1 filed May 15, 2025
- Boxer Capital Management 2024 Q4 filed Feb. 14, 2025